Vivos Therapeutics Inc (NASDAQ:VVOS) had positive Q3 2024 results, with increased revenue and gross margin, reduced operating expenses, and FDA clearance for treating severe OSA.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Vivos Therapeutics Inc (NASDAQ:VVOS) had positive Q3 2024 results, with increased revenue and gross margin, reduced operating expenses, and FDA clearance for treating severe OSA.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
We are preparing, please wait
This content is only available for premium members. Please become a paid member to access.
Download AppCurrently, memberships can only be purchased through the app.